Mate share price doesn't really tell the full story.
The market cap has fallen from high of $aud62 million to the present $aud 20million due to dilution.
This was an illiquid stock, which added to risk. Previously no to mid thousands of shares would trade per day, Now we see millions of shares traded per day. So the dilution is bad for early holders, but has derisked for buyers down here. Such is early life drug discovery biotech companies. When you have no income stream there will be dilution.
Mate share price doesn't really tell the full story. The...
-
- There are more pages in this discussion • 170 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
